Esperion Therapeutics (ESPR) Net Income towards Common Stockholders (2012 - 2026)

Esperion Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$26.4 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 36.48% year-over-year to -$26.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (up 91.86% YoY) and the FY2025 annual result came in at -$22.7 million, up 56.17% from the prior year.
• Net Income towards Common Stockholders was -$26.4 million for Q1 2026 at Esperion Therapeutics, down from $62.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $62.6 million in Q4 2025 and bottomed at -$66.6 million in Q2 2022.
• A 5-year average of -$30.3 million and a median of -$41.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 315.28% in 2025, while the deepest fall reached 171.3% in 2025.
• Esperion Therapeutics' Net Income towards Common Stockholders stood at -$56.8 million in 2022, then decreased by 1.02% to -$57.4 million in 2023, then soared by 49.36% to -$29.1 million in 2024, then soared by 315.28% to $62.6 million in 2025, then slumped by 142.14% to -$26.4 million in 2026.
• Business Quant data shows ESPR's Net Income towards Common Stockholders at -$26.4 million in Q1 2026, $62.6 million in Q4 2025, and -$32.0 million in Q3 2025.